ProfileGDS4814 / ILMN_1784216
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 68% 70% 68% 69% 67% 67% 72% 69% 69% 64% 68% 68% 76% 69% 76% 77% 68% 76% 68% 69% 68% 68% 68% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)68.473668
GSM780708Untreated after 4 days (C2_1)71.827970
GSM780709Untreated after 4 days (C3_1)67.233268
GSM780719Untreated after 4 days (C1_2)71.440969
GSM780720Untreated after 4 days (C2_2)64.446767
GSM780721Untreated after 4 days (C3_2)64.909767
GSM780710Trastuzumab treated after 4 days (T1_1)82.128872
GSM780711Trastuzumab treated after 4 days (T2_1)70.559869
GSM780712Trastuzumab treated after 4 days (T3_1)70.038769
GSM780722Trastuzumab treated after 4 days (T1_2)59.455864
GSM780723Trastuzumab treated after 4 days (T2_2)66.46668
GSM780724Trastuzumab treated after 4 days (T3_2)67.28468
GSM780713Pertuzumab treated after 4 days (P1_1)106.89376
GSM780714Pertuzumab treated after 4 days (P2_1)70.202669
GSM780715Pertuzumab treated after 4 days (P3_1)105.65976
GSM780725Pertuzumab treated after 4 days (P1_2)111.12677
GSM780726Pertuzumab treated after 4 days (P2_2)67.739468
GSM780727Pertuzumab treated after 4 days (P3_2)102.13776
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)66.815968
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)68.741969
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)66.057768
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)68.324468
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)65.948668